Incyte’s Phase 3 TRuE-PN trials show ruxolitinib cream improves itch relief in prurigo nodularis, though TRuE-PN2’s primary endpoint fell short.
Latest Ratings for INCY
DateFirmActionFromTo Feb 2022SVB LeerinkDowngradesMarket PerformUnderperform Feb 2022Morgan StanleyMaintainsEqual-Weight Jan 2022RBC CapitalUpgradesSector PerformOutperform